HAYA Therapeutics announced multi-year collaboration with Eli Lilly applying HAYA's regulatory genome RNA platform to preclinical obesity and metabolic drug discovery. HAYA receives upfront + equity investment and is eligible for up to $1B in preclinical, clinical, and commercial milestones plus royalties.
Key facts
AnnouncedSep 04, 2024
ClosedSep 04, 2024
Deal value$1.0B
Deal typeCo-Development
Therapeutic areaObesity and related metabolic conditions
IndicationsObesity and related metabolic conditions
Key assetsRNA-based drug targets from regulatory genome platform (lncRNA targets)